234 related articles for article (PubMed ID: 20448669)
41. The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner.
Hsu FY; Johnston PB; Burke KA; Zhao Y
Cancer Res; 2006 Sep; 66(18):9002-8. PubMed ID: 16982741
[TBL] [Abstract][Full Text] [Related]
42. Hypoxia-microRNA-16 downregulation induces VEGF expression in anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphomas.
Dejean E; Renalier MH; Foisseau M; Agirre X; Joseph N; de Paiva GR; Al Saati T; Soulier J; Desjobert C; Lamant L; Prósper F; Felsher DW; Cavaillé J; Prats H; Delsol G; Giuriato S; Meggetto F
Leukemia; 2011 Dec; 25(12):1882-90. PubMed ID: 21778999
[TBL] [Abstract][Full Text] [Related]
43. Involvement of oncogenic tyrosine kinase NPM-ALK in trifluoperazine-induced cell cycle arrest and apoptosis in ALK
Hu L; Zhang X; Wang J; Wang S; Amin HM; Shi P
Hematology; 2018 Jun; 23(5):284-290. PubMed ID: 29086626
[TBL] [Abstract][Full Text] [Related]
44. Whole Exome Sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target.
Larose H; Prokoph N; Matthews JD; Schlederer M; Högler S; Alsulami AF; Ducray SP; Nuglozeh E; Fazaludeen FMS; Elmouna A; Ceccon M; Mologni L; Gambacorti-Passerini C; Hoefler G; Lobello C; Pospisilova S; Janikova A; Woessmann W; Damm-Welk C; Zimmermann M; Federova A; Malone A; Smith O; Wasik M; Inghirami G; Lamant L; Blundell TL; Klapper W; Merkel O; Burke AGA; Mian S; Ashankyty I; Kenner L; Turner SD
Haematologica; 2021 Jun; 106(6):1693-1704. PubMed ID: 32327503
[TBL] [Abstract][Full Text] [Related]
45. Caspase-3 activation in systemic anaplastic large-cell lymphoma.
Drakos E; Rassidakis GZ; Lai R; Herling M; O'Connor SL; Schmitt-Graeff A; McDonnell TJ; Medeiros LJ
Mod Pathol; 2004 Jan; 17(1):109-16. PubMed ID: 14657946
[TBL] [Abstract][Full Text] [Related]
46. Identification of a novel crosstalk between casein kinase 2α and NPM-ALK in ALK-positive anaplastic large cell lymphoma.
Armanious H; Gelebart P; Anand M; Lai R
Cell Signal; 2013 Feb; 25(2):381-8. PubMed ID: 23153582
[TBL] [Abstract][Full Text] [Related]
47. Aberrant expression of the transcriptional factor Twist1 promotes invasiveness in ALK-positive anaplastic large cell lymphoma.
Zhang J; Wang P; Wu F; Li M; Sharon D; Ingham RJ; Hitt M; McMullen TP; Lai R
Cell Signal; 2012 Apr; 24(4):852-8. PubMed ID: 22155737
[TBL] [Abstract][Full Text] [Related]
48. Aberrant expression of GOLM1 protects ALK+ anaplastic large cell lymphoma from apoptosis by enhancing BCL-XL stability.
Zi Z; Du S; Zhang L; Wang Y; Ding L; Zhang C; Wang H; Pawlicki J; Cai Y; Yao Y; Zhou F; Tong Y; Riley JL; Cai Q; Ma X; Wei F
Blood Adv; 2023 Aug; 7(15):4049-4063. PubMed ID: 36763539
[TBL] [Abstract][Full Text] [Related]
49. Molecular biology of anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma.
Kutok JL; Aster JC
J Clin Oncol; 2002 Sep; 20(17):3691-702. PubMed ID: 12202671
[TBL] [Abstract][Full Text] [Related]
50. The Long Non-Coding RNA MIR503HG Enhances Proliferation of Human ALK-Negative Anaplastic Large-Cell Lymphoma.
Huang PS; Chung IH; Lin YH; Lin TK; Chen WJ; Lin KH
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29758012
[TBL] [Abstract][Full Text] [Related]
51. Constitutive control of AKT1 gene expression by JUNB/CJUN in ALK+ anaplastic large-cell lymphoma: a novel crosstalk mechanism.
Atsaves V; Zhang R; Ruder D; Pan Y; Leventaki V; Rassidakis GZ; Claret FX
Leukemia; 2015 Nov; 29(11):2162-72. PubMed ID: 25987255
[TBL] [Abstract][Full Text] [Related]
52. Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma.
Eckerle S; Brune V; Döring C; Tiacci E; Bohle V; Sundström C; Kodet R; Paulli M; Falini B; Klapper W; Chaubert AB; Willenbrock K; Metzler D; Bräuninger A; Küppers R; Hansmann ML
Leukemia; 2009 Nov; 23(11):2129-38. PubMed ID: 19657361
[TBL] [Abstract][Full Text] [Related]
53. CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.
Cheng M; Quail MR; Gingrich DE; Ott GR; Lu L; Wan W; Albom MS; Angeles TS; Aimone LD; Cristofani F; Machiorlatti R; Abele C; Ator MA; Dorsey BD; Inghirami G; Ruggeri BA
Mol Cancer Ther; 2012 Mar; 11(3):670-9. PubMed ID: 22203728
[TBL] [Abstract][Full Text] [Related]
54. Pathobiology of ALK+ anaplastic large-cell lymphoma.
Amin HM; Lai R
Blood; 2007 Oct; 110(7):2259-67. PubMed ID: 17519389
[TBL] [Abstract][Full Text] [Related]
55. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features.
Stein H; Foss HD; Dürkop H; Marafioti T; Delsol G; Pulford K; Pileri S; Falini B
Blood; 2000 Dec; 96(12):3681-95. PubMed ID: 11090048
[TBL] [Abstract][Full Text] [Related]
56. A novel ALK inhibitor ZYY inhibits Karpas299 cell growth in vitro and in a mouse xenograft model and induces protective autophagy.
Shen J; Wang J; Du J; Wang L; Zhou X; Chang X; Li Z; Zhai X; Zuo D; Wu Y
Toxicol Appl Pharmacol; 2019 Nov; 383():114781. PubMed ID: 31618659
[TBL] [Abstract][Full Text] [Related]
57. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
[TBL] [Abstract][Full Text] [Related]
58. Molecular characterization of the t(2;5) (p23; q35) translocation in anaplastic large cell lymphoma (Ki-1) and Hodgkin's disease.
Yee HT; Ponzoni M; Merson A; Goldstein M; Scarpa A; Chilosi M; Menestrina F; Pittaluga S; de Wolf-Peeters C; Shiota M; Mori S; Frizzera G; Inghirami G
Blood; 1996 Feb; 87(3):1081-8. PubMed ID: 8562933
[TBL] [Abstract][Full Text] [Related]
59. The ALK inhibitor ASP3026 eradicates NPM-ALK⁺ T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model.
George SK; Vishwamitra D; Manshouri R; Shi P; Amin HM
Oncotarget; 2014 Jul; 5(14):5750-63. PubMed ID: 25026277
[TBL] [Abstract][Full Text] [Related]
60. Lack of TNFalpha expression protects anaplastic lymphoma kinase-positive T-cell lymphoma (ALK+ TCL) cells from apoptosis.
Zhang Q; Wang HY; Bhutani G; Liu X; Paessler M; Tobias JW; Baldwin D; Swaminathan K; Milone MC; Wasik MA
Proc Natl Acad Sci U S A; 2009 Sep; 106(37):15843-8. PubMed ID: 19717436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]